Drug Profile
E 7016
Alternative Names: E-7016; GPI-21016Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator MGI GP
- Developer Eisai Co Ltd
- Class Antineoplastics
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glioma; Solid tumours
- Discontinued Malignant melanoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Glioma(Combination therapy, Late-stage disease) in USA (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in USA (PO)
- 31 Mar 2012 Phase-II clinical trials in Malignant melanoma in USA (PO)